Liraglutide

Published results showed exercise in combination with glucagon-like peptide-1 receptor agonist treatment may be an effective weight loss strategy that preserves clinically relevant site-specific bone mineral density.

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

A “heat dome” like the one that descended over the Northeast and Midwest United States may increase cardiovascular risk, especially in vulnerable populations, according to Jonathan Newman, MD, MPH.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.

Adults who previously used an obesity medication before receiving semaglutide lost less body weight at 12 months than those who did not use an obesity medication before semaglutide, according to study findings.

Most adults with obesity were not prescribed an obesity medication from 2015 to 2023, and of those prescribed an agent, 55% had at least one prescription fill, according to study data published in Diabetes, Obesity and Metabolism.

Over half of patients who stopped taking liraglutide or semaglutide were able to maintain their weight for a year, according to a recent study from Epic Research.

More than 80% of adults who are prescribed an obesity medication discontinue taking them at 1 year, though persistence rates are higher for adults receiving semaglutide and liraglutide, according to study data.

PHILADELPHIA — Adults with obesity and atrial fibrillation treated with liraglutide plus risk factor modification had improved outcomes after catheter ablation compared with those prescribed risk factor modification alone.